Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Director/PDMR Shareholding

12 Dec 2006 18:33

ReGen Therapeutics PLC12 December 2006 Notification of Change in Interests of Directors London: On 12 December 2006 options ("Options") were granted to directors of theCompany in respect of an aggregate of 43,200,000 ordinary shares of 0.1p each inthe Company ("Ordinary Shares"). The Options, taken with existing options andwarrants over Ordinary Shares, will, if exercised, represent 5.77 per cent ofthe then enlarged issued share capital of the Company. All Options were granted with an exercise price of 1.25p per Ordinary Share (theclosing mid-market price on 12 December 2006) and may normally be exercisedbetween 31 December 2007 and 12 December 2016. The exercise of all Options issubject to first meeting performance conditions based on product launch andachieving certain revenue and profit targets over 2007, 2008 and 2009. Prior toreceiving these grants the executive Directors cancelled all previously grantedoptions (which were not subject to performance targets). No amounts were paid for the grants themselves. Percy Lomax was granted 13,000,000 Options. Following this announcement Mr Lomaxholds a total of 2,282,069 Ordinary Shares (representing 0.33 per cent of issuedshare capital) and 13,000,000 options over Ordinary Shares in the capital of theCompany. Timothy Shilton was granted 9,000,000 Options. Following this announcement MrShilton holds a total of 500,000 Ordinary Shares (representing 0.07 per cent ofissued share capital) and 9,000,000 options over Ordinary Shares in the capitalof the Company. Norman Lott was granted 8,000,000 Options. Following this announcement Mr Lottholds a total of 182,000 Ordinary Shares (representing 0.026 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Martin Small was granted 8,000,000 Options. Following this announcement Mr Smallholds a total of 2,248,736 Ordinary Shares (representing 0.32 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Keith Corbin was granted 2,700,000 Options. Following this announcement MrCorbin holds a total of 1,105,000 Ordinary Shares (representing 0.16 per cent ofissued share capital) and 3,300,000 options over Ordinary Shares in the capitalof the Company. Peter Garrod was granted 2,500,000 Options. Following this announcement MrGarrod holds a total of 66,750,000 Ordinary Shares (representing 9.61 per centof issued share capital) and 2,500,000 options over Ordinary Shares in thecapital of the Company. Further Information Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.